Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This case study highlights lorlatinib
Area Of Science
- Oncology
- Pulmonary Medicine
- Genetics
Background
- Pulmonary mucoepidermoid carcinoma (PMEC) is a rare lung cancer with no established treatment guidelines.
- Limited clinical data exists for PMEC due to its low incidence.
Observation
- A 59-year-old female never-smoker presented with cough and hemoptysis.
- Diagnosis confirmed as advanced high-grade PMEC.
- Genetic testing revealed an echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion, variant E20:A20 (V2).
Findings
- The patient received first-line treatment with lorlatinib.
- Lorlatinib demonstrated effectiveness in treating this specific PMEC subtype.
Implications
- This is the first reported case of lorlatinib's efficacy in advanced high-grade PMEC with EML4-ALK fusion V2.
- Suggests a potential targeted therapy option for PMEC patients with this genetic mutation.
- May inform future treatment strategies for rare lung cancers.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...